EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Kynurenine Pathway in Diabetes Mellitus—Novel Pharmacological Target?

Kamila Kozieł, Ewa M Urbanska iD

Cells · 31.01.2023 · 12 (3) · 460

DOI: 10.3390/cells12030460 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 31.01.2023. Verfasst von Kamila Kozieł und 1 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Cellular and Molecular Pharmacology, Chair and Department of Clinical and Experimental Pharmacology, Medical University, 20-090 Lublin,…. Hauptthemen laut MEDLINE: Nervous System Diseases, Diabetic Retinopathy, Diabetes Mellitus. Die Arbeit wurde bisher 91-mal zitiert (Crossref) und nennt 201 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University in Lublin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The tryptophan–kynurenine pathway (Trp–KYN) is the major route for tryptophan conversion in the brain and in the periphery. Kynurenines display a wide range of biological actions (which are often contrasting) such as cytotoxic/cytoprotective, oxidant/antioxidant or pro-/anti-inflammatory. The net effect depends on their local concentration, cellular environment, as well as a complex positive and negative feedback loops. The imbalance between beneficial and harmful kynurenines was implicated in the pathogenesis of various neurodegenerative disorders, psychiatric illnesses and metabolic disorders, including diabetes mellitus (DM). Despite available therapies, DM may lead to serious macro- and microvascular complications including cardio- and cerebrovascular disease, peripheral vascular disease, chronic renal disease, diabetic retinopathy, autonomic neuropathy or cognitive impairment. It is well established that low-grade inflammation, which often coincides with DM, can affect the function of KP and, conversely, that kynurenines may modulate the immune response. This review provides a detailed summary of findings concerning the status of the Trp–KYN pathway in DM based on available animal, human and microbiome studies. We highlight the importance of the molecular interplay between the deranged (functionally and qualitatively) conversion of Trp to kynurenines in the development of DM and insulin resistance. The Trp–KYN pathway emerges as a novel target in the search for preventive and therapeutic interventions in DM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nervous System DiseasesDiabetic RetinopathyDiabetes MellitusAnimalsHumansKynurenineTryptophanBrain

Stichwörter der Autor:innen

3-hydroxykynureninediabetes mellitusindoleamine 2,3-dioxygenaseinflammatorykynurenic acidkynureninekynurenine aminotransferasemetabolismneurodegenerationquinolinic acid

Substanzen

KynurenineTryptophan

Autor:innen und Institutionen

  • Laboratory of Cellular and Molecular Pharmacology, Chair and Department of Clinical and Experimental Pharmacology, Medical University, 20-090 Lublin, Poland.

ORCID-Profile: Ewa M Urbanska

Förderung

  • Medical University in Lublin

Zitieren

APA

Kozieł, K., & Urbanska, E. M. (2023). Kynurenine Pathway in Diabetes Mellitus—Novel Pharmacological Target?. Cells, 12(3), 460. https://doi.org/10.3390/cells12030460

Vancouver

Kozieł K, Urbanska EM. Kynurenine Pathway in Diabetes Mellitus—Novel Pharmacological Target?. Cells. 2023;12(3):460. doi:10.3390/cells12030460

BibTeX
@article{Kozie2023,
  author = {Kozieł, Kamila and Urbanska, Ewa M},
  title = {Kynurenine Pathway in Diabetes Mellitus—Novel Pharmacological Target?},
  journal = {Cells},
  year = {2023},
  volume = {12},
  number = {3},
  pages = {460},
  doi = {10.3390/cells12030460}
}
Kostenlos starten →